MCID: XLN206
MIFTS: 33

X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards integrated aliases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

Name: X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome 59
Johnson Syndrome 59

Characteristics:

Orphanet epidemiological data:

59
x-linked intellectual disability-macrocephaly-macroorchidism syndrome
Inheritance: X-linked recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 34 Q87.8
Orphanet 59 ORPHA85320

Summaries for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards based summary : X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome, also known as johnson syndrome, is related to dubin-johnson syndrome and stevens-johnson syndrome/toxic epidermal necrolysis. The drugs Gabapentin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and liver, and related phenotypes are macrocephaly and macroorchidism

Related Diseases for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 dubin-johnson syndrome 12.9
2 stevens-johnson syndrome/toxic epidermal necrolysis 12.8
3 severe cutaneous adverse reaction 12.5
4 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 12.4
5 erythema multiforme 12.2
6 erythema multiforme major 11.9
7 hyperbilirubinemia, rotor type 11.6
8 bilirubin metabolic disorder 11.6
9 gilbert syndrome 11.5
10 5-oxoprolinase deficiency 11.2
11 crigler-najjar syndrome, type ii 11.2
12 auditory neuropathy spectrum disorder 11.2
13 exanthem 10.7
14 conjunctivitis 10.5
15 allergic hypersensitivity disease 10.4
16 mucositis 10.4
17 cholestasis 10.4
18 yemenite deaf-blind hypopigmentation syndrome 10.4
19 lupus erythematosus 10.4
20 systemic lupus erythematosus 10.4
21 bronchiolitis 10.4
22 bronchiolitis obliterans 10.3
23 hypereosinophilic syndrome 10.3
24 skin disease 10.3
25 keratitis, hereditary 10.3
26 bullous pemphigoid 10.3
27 herpes simplex 10.3
28 stomatitis 10.3
29 respiratory failure 10.3
30 dermatitis 10.3
31 pneumonia 10.3
32 liver disease 10.2
33 acute generalized exanthematous pustulosis 10.2
34 neutropenia 10.2
35 entropion 10.2
36 dysphagia 10.2
37 limbal stem cell deficiency 10.2
38 ocular cicatricial pemphigoid 10.2
39 acute kidney failure 10.2
40 drug reaction with eosinophilia and systemic symptoms 10.2
41 autoimmune disease 10.2
42 autosomal recessive disease 10.2
43 corneal neovascularization 10.2
44 lung disease 10.2
45 immune deficiency disease 10.1
46 cicatricial pemphigoid 10.1
47 purpura 10.1
48 endophthalmitis 10.1
49 cataract 10.1
50 major affective disorder 8 10.1

Graphical network of the top 20 diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:



Diseases related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Symptoms & Phenotypes for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Human phenotypes related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macrocephaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0000256
2 macroorchidism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000053
3 intellectual disability, moderate 59 32 hallmark (90%) Very frequent (99-80%) HP:0002342

Drugs & Therapeutics for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Drugs for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Azithromycin Approved Phase 4 83905-01-5 447043 55185
3
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
4
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
5
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
8 Ophthalmic Solutions Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antimetabolites Phase 4
11 Analgesics Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Psychotropic Drugs Phase 4
14 Tranquilizing Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 Anti-Anxiety Agents Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Anticonvulsants Phase 4
19 Antimanic Agents Phase 4
20 Excitatory Amino Acids Phase 4
21 Analgesics, Opioid Phase 4
22 Cytochrome P-450 Enzyme Inducers Phase 4
23 Lipid Regulating Agents Phase 4
24 Hypolipidemic Agents Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Neurotransmitter Agents Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Sodium Channel Blockers Phase 4
29 Autonomic Agents Phase 4
30 Anti-Arrhythmia Agents Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Adrenergic Agents Phase 4
33 Adrenergic Antagonists Phase 4
34 Sympatholytics Phase 4
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
36
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
37
Lesinurad Approved, Investigational Phase 3 878672-00-5 53465279
38
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
39
Etravirine Approved Phase 3 269055-15-4 193962
40
tannic acid Approved Phase 2, Phase 3 1401-55-4
41
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
42
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
43
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
44
Etanercept Approved, Investigational Phase 3 185243-69-0
45
Coal tar Approved Phase 3 8007-45-2
46
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
47
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
48 Hypoglycemic Agents Phase 3
49 Antirheumatic Agents Phase 3
50 Renal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
2 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
3 Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction Completed NCT01977937 Phase 4 Gabapentin 250mg/5mL NDC:59762-5025-01;Simple Syrup
4 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
5 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
6 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Recruiting NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
7 Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial Recruiting NCT03810235 Phase 4 Transdermal Lidocaine Patch;Transdermal Hydrocolloid Placebo Patch
8 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
10 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
11 Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction Completed NCT01237600 Phase 2, Phase 3
12 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
13 A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor Completed NCT01508702 Phase 3 lesinurad;Placebo
14 A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125. Completed NCT00792324 Phase 3 Etravirine;Efavirenz
15 Maraviroc to Augment Rehabilitation Outcomes After Stroke Recruiting NCT03172026 Phase 2, Phase 3 Maraviroc 300 mg;Placebo 300 mg
16 Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults Not yet recruiting NCT02987257 Phase 3 cyclosporin A;Etanercept 50 MG Solution for Injection;Placebos
17 Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study Terminated NCT00295776 Phase 2, Phase 3 Lamictal in the treatment of Post-Herpetic Neuralgia
18 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
19 Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial) Completed NCT02746848 Phase 1, Phase 2
20 Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan Completed NCT00130013 Phase 1, Phase 2 Oral Amoxicillin
21 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
22 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
23 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
24 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
25 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
26 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction Completed NCT00344201 Phase 1
27 Topical Infliximab for the Treatment of Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
28 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Not yet recruiting NCT03878771 Phase 1 Dermovate cream in Orabase
29 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
30 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
31 Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Unknown status NCT03176342
32 Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity. Unknown status NCT03166241
33 The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation Unknown status NCT00696982 sitagliptin;glibenclamide
34 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
35 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
36 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR) Completed NCT01276314 anti- TNF-a;Prednisolone
37 Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy Completed NCT00822432
38 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
39 Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases Completed NCT00357071
40 Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye Completed NCT02219204
41 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Recruiting NCT02574988
42 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
43 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
44 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Recruiting NCT02795143 Isotretinoin
45 The Effects of Autologous Simple Limbal Epithelial Transplantation. Recruiting NCT04021875
46 The Effects of Allogeneic Simple Limbal Epithelial Transplantation Recruiting NCT04021134
47 Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study Recruiting NCT01611636
48 HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study Recruiting NCT03184597
49 An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
50 Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting Recruiting NCT03041883

Search NIH Clinical Center for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome

Genetic Tests for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Anatomical Context for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

MalaCards organs/tissues related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

41
Skin, Eye, Liver, Testes, T Cells, Lung, Salivary Gland

Publications for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Articles related to X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome:

(show top 50) (show all 3864)
# Title Authors PMID Year
1
Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 38
30632424 2019
2
Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 38
31195022 2019
3
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
31254013 2019
4
Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 38
31332981 2019
5
Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review. 38
31331726 2019
6
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 38
30086678 2019
7
Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. 38
30809807 2019
8
Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. 38
30825193 2019
9
Predicting sepsis in Stevens-Johnson syndrome-toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin? 38
31420075 2019
10
Histomorphological Changes in Lachrymal Glands of Patients With Chronic Stevens-Johnson Syndrome. 38
31232745 2019
11
Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 38
31150704 2019
12
Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 38
31041733 2019
13
Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 38
31387802 2019
14
Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate. 38
31396952 2019
15
Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review. 38
31436331 2019
16
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 38
31387950 2019
17
A review and guide to drug-associated oral adverse effects-Oral mucosal and lichenoid reactions. Part 2. 38
31241804 2019
18
Identification of drug-specific public TCR driving severe cutaneous adverse reactions. 38
31395875 2019
19
Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 38
31020549 2019
20
Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 38
31247634 2019
21
HLA-B*58:01 Genotyping to Prevent Cases of DRESS and SJS/TEN in East Asians Treated with Allopurinol-A Canadian Missed Opportunity. 38
31378082 2019
22
Drug hypersensitivity in HIV infection. 38
31145192 2019
23
Long-term effect of corneoscleral contact lenses on refractory ocular surface diseases. 38
30389416 2019
24
Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. 38
30998617 2019
25
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. 38
29912772 2019
26
Contribution to oral and maxillary surgery and surgical technique of osteo-odontokeratoprosthesis in Japan. 38
31378404 2019
27
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 38
30785787 2019
28
Stevens-Johnson Syndrome and Treatment With Clopidogrel. 38
30119955 2019
29
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. 38
30918988 2019
30
Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 38
31434673 2019
31
Altered retinoid metabolism gene expression in chronic Stevens-Johnson syndrome. 38
31023710 2019
32
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 38
31404173 2019
33
Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. 38
31158306 2019
34
Direct in situ labeling of target drugs with a fluorophore probe to improve MALDI-MS detection sensitivity in micro-liter plasma. 38
31346224 2019
35
Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
30613954 2019
36
Trends in mortality rates for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): experience of a single center in France between 1997 and 2017. 38
31323695 2019
37
British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. 38
30829411 2019
38
Individual and hospital-level factors associated with epidermal necrolysis mortality: a Nationwide Multi-Level Study, France, 2012-2016. 38
31260078 2019
39
Genetic testing for prevention of severe drug-induced skin rash. 38
31314143 2019
40
Controlling oral haemorrhage in Steven Johnson syndrome/ Toxic Epidermal Necrolysis. 38
31279017 2019
41
[Warning symptoms skin: cutaneous manifestation of drug allergy]. 38
31282839 2019
42
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. 38
31327687 2019
43
Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 38
31352606 2019
44
Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis. 38
31326519 2019
45
Corneal higher-order aberrations in Stevens-Johnson syndrome and toxic epidermal necrolysis. 38
31325631 2019
46
Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. 38
31356413 2019
47
Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. 38
31384575 2019
48
Erythema Multiforme: Recognition and Management. 38
31305041 2019
49
[Allergies to non-betalactam antibiotics: a challenge in practice]. 38
31282834 2019
50
Intravenous cyclosporine in treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series. 38
31070856 2019

Variations for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Expression for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Search GEO for disease gene expression data for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism Syndrome.

Pathways for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

GO Terms for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

Sources for X-Linked Intellectual Disability-Macrocephaly-Macroorchidism...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....